CN103992372A - Dipeptide GT with function of decreasing blood glucose and application thereof - Google Patents
Dipeptide GT with function of decreasing blood glucose and application thereof Download PDFInfo
- Publication number
- CN103992372A CN103992372A CN201410245073.7A CN201410245073A CN103992372A CN 103992372 A CN103992372 A CN 103992372A CN 201410245073 A CN201410245073 A CN 201410245073A CN 103992372 A CN103992372 A CN 103992372A
- Authority
- CN
- China
- Prior art keywords
- dipeptides
- alpha
- dipeptide
- glucosidase
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses dipeptide GT. The amino acid sequence of dipeptide GT is Gly-Thr. The invention also provides an application of dipeptide GT in preparing medicaments for decreasing blood glucose. Dipeptide GT can be used as alpha-glucosidase inhibitory peptide.
Description
Technical field
The invention belongs to biological technical field, particularly an energy is combined with alpha-glucosidase, suppresses its active dipeptides GT.
Background technology
One of main source of blood sugar is small intestine to the digesting and assimilating of carbohydrate, and the carbohydrate such as starch resolve into monose through alpha-glucosidase, by intestinal absorption, enter blood circulation.Therefore alpha-glucosidase generates in glucose and has vital role in carbohydrate metabolism.Alpha-glucosidase inhibitor can be by suppressing the activity of alpha-glucosidase in human small intestine's epithelium chorion brush border, the generation of delay glucose, in reducing postprandial blood sugar, have vital role, alpha-glucosidase inhibitor is widely used in treating diabetes at present.
Hypoglycemic medicine common are:
1. alpha-glucosidase inhibitor: acarbose, voglibose and miglitol etc.
2. Regular Insulin promotor: repaglinide, nateglinide, glimepiride, gliquidone etc.
3. euglycemic agent: N1,N1-Dimethylbiguanide, thiazolidinediones etc.
4. Regular Insulin and analogue thereof: Regular Insulin, Insulin lispro, insulin aspart, glulisine etc.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of two peptide sequence GT with function of blood sugar reduction and uses thereof.
In order to solve the problems of the technologies described above, the invention provides a kind of dipeptides GT, the aminoacid sequence of this dipeptides GT is: Gly-Thr.
The present invention also provides the application of above-mentioned dipeptides GT in preparing hypoglycemic drug simultaneously.
Improvement as the application of dipeptides GT of the present invention: preparation is as the medicine of alpha-glucosaccharase enzyme inhibition peptide.
That is, the present invention also provides the purposes of above-mentioned dipeptides GT simultaneously: as alpha-glucosaccharase enzyme inhibition peptide.
Dipeptides GT of the present invention can be by entrusting synthetic acquisition of the biochemical (Shanghai) Co., Ltd. of gill.
Two peptide sequences that the present invention reports are to have and suppress active for alpha-glucosidase, thereby show the characteristic with function of blood sugar reduction.
In the present invention, related alpha-glucosidase suppresses active detection method:
Get respectively the certain density polypeptide solution of 50 μ L (0.1mol/L, the configuration of pH=6.9 phosphoric acid buffer), the alpha-glucosaccharase enzyme solution of 100 μ L10mg/mL is (with 0.1mol/L, the preparation of pH=6.9 phosphoric acid buffer), add in enzyme plate, after mixing, place 10min at 25 ℃.Then add 50 μ L5mmol/L PNPG (p-nitrophenyl-α-D-glucopyranoside) solution (with 0.1mol/L, the preparation of pH=6.9 phosphoric acid buffer), cultivate after 30min at 37 ℃, add the Na of 50 μ L0.67mol/L
2cO
3solution termination reaction, measures absorbancy under 405nm.This system is called sample.
Following 3 individual system are set simultaneously: contrast, sample blank and contrast are blank.
Contrast: with 50 μ L0.1mol/L, pH=6.9 phosphoric acid buffer substitutes the polypeptide solution of 50 μ L.
Sample blank: with the 0.1mol/L of 100 μ L, pH=6.9 phosphoric acid buffer replaces the alpha-glucosaccharase enzyme solution of 100 μ L10mg/mL;
Contrast is blank: with the 0.1mol/L of respective volume amount, pH=6.9 phosphoric acid buffer replaces polypeptide solution and alpha-glucosaccharase enzyme solution respectively, and inhibiting rate is calculated as follows.
Advantage of the present invention and positively effect: the activity that this dipeptides GT can Inhibiting α-glucosidase.
According to aminoacid sequence of the present invention, can entrust the biochemical (Shanghai) Co., Ltd. of gill synthetic, thereby obtain alpha-glucosaccharase enzyme inhibition peptide of the present invention (or referred to as dipeptides GT).
Usage and the consumption of alpha-glucosaccharase enzyme inhibition peptide of the present invention (or referred to as dipeptides GT) are as follows:
Dipeptides of the present invention is oral type, and consumption is oral, each 2g, every day 2～3 times.
Embodiment
Embodiment 1,
The alpha-glucosidase of dipeptides GT under the concentration of 1.0mg/mL suppresses active:
Detection method: by this dipeptides GT obtaining by chemical synthesis, carry out activity and detect (detection method is the same).Now GT concentration is 1.0mg/mL.
Result: it is 33.6% that the alpha-glucosidase of dipeptides GT when 1.0mg/mL suppresses activity.
Embodiment 2,
The alpha-glucosidase of dipeptides GT under the concentration of 2.0mg/mL suppresses active:
Detection method: will obtain this dipeptides GT by chemical synthesis, and carry out activity and detect (detection method is the same).Now GT concentration is 2.0mg/mL.
Result: it is 65.2% that the alpha-glucosidase of dipeptides GT when 2.0mg/mL suppresses activity.
By inhibition concentration and activity data in embodiment 1 and embodiment 2, activity and the concentration amount effect relationship of this dipeptides GT are described, this dipeptides GT has alpha-glucosidase inhibition activity and has no report, belongs to the new alpha-glucosidase that has and suppresses active function peptide.
Comparative example 1, dipeptides TA (detection method is the same)
It is 15.2% that the alpha-glucosidase of dipeptides TA when 1.0mg/mL suppresses activity; It is 31.5% that alpha-glucosidase when 2.0mg/mL suppresses activity.
Finally, it is also to be noted that, what more than enumerate is only several specific embodiments of the present invention.Obviously, the invention is not restricted to above embodiment, can also have many distortion, such as separating obtained GT structure and the derivatize structure thereof of different proteins source degraded.All distortion that those of ordinary skill in the art can directly derive or associate from content disclosed by the invention, all should think protection scope of the present invention.
<110> Zhejiang Academy of Agricultural Science
<120> has dipeptides GT of function of blood sugar reduction and uses thereof
<160>?1
<210>?1
<211>?2
<212>?PRT
<213> artificial sequence
<220>
<223> dipeptides GT
<400>?1
Gly?Thr
Claims (3)
1. dipeptides GT, is characterized in that the aminoacid sequence of this dipeptides GT is: Gly-Thr.
2. the application of dipeptides GT as claimed in claim 1 in preparing hypoglycemic drug.
3. the application of dipeptides GT according to claim 2, is characterized in that: preparation is as the medicine of alpha-glucosaccharase enzyme inhibition peptide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410245073.7A CN103992372A (en) | 2014-06-05 | 2014-06-05 | Dipeptide GT with function of decreasing blood glucose and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410245073.7A CN103992372A (en) | 2014-06-05 | 2014-06-05 | Dipeptide GT with function of decreasing blood glucose and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103992372A true CN103992372A (en) | 2014-08-20 |
Family
ID=51306736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410245073.7A Pending CN103992372A (en) | 2014-06-05 | 2014-06-05 | Dipeptide GT with function of decreasing blood glucose and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103992372A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107011413A (en) * | 2017-05-31 | 2017-08-04 | 浙江省农业科学院 | Tripeptides CGP with function of blood sugar reduction and application thereof |
| CN111187335A (en) * | 2019-09-19 | 2020-05-22 | 浙江省农业科学院 | Zein source dipeptide LK and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019123A (en) * | 2004-02-06 | 2007-08-15 | 科学与工业研究委员会 | Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential |
| CN101035543A (en) * | 2004-08-10 | 2007-09-12 | 麦迪库瑞国际公司 | Combination therapies employing vitamin B6 related compounds and ACE inhibitors and uses thereof for the treatment of diabetic disorders |
-
2014
- 2014-06-05 CN CN201410245073.7A patent/CN103992372A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019123A (en) * | 2004-02-06 | 2007-08-15 | 科学与工业研究委员会 | Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential |
| CN101035543A (en) * | 2004-08-10 | 2007-09-12 | 麦迪库瑞国际公司 | Combination therapies employing vitamin B6 related compounds and ACE inhibitors and uses thereof for the treatment of diabetic disorders |
Non-Patent Citations (4)
| Title |
|---|
| HONG GT等: "Hydrolysis of Dipeptides catalyzed by a Zirconium(iv)-substituted Lindqvist type polyoxometalate", 《EUROPEAN JOURNAL OF INORGANIC CHEMISTRY》 * |
| JORGE AV等: "Protein nutrition and amino acid metabolism after 4 weeks of total parenteral nutrition with a mixture of 14 dipeptides:serendipitous observations on effects of sepsis in baboons", 《THE AMERICAN JOURNAL OF CLINICAL NUTRITION》 * |
| 刘静等: "基于多元线性回归的血管紧张素转化酶抑制剂定量构效关系建模研究", 《分析科学学报》 * |
| 吴永贵等: "血管紧张素转换酶抑制剂对糖尿病大鼠肾皮质细胞膜胰岛素受体的调节", 《中华内分泌代谢杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107011413A (en) * | 2017-05-31 | 2017-08-04 | 浙江省农业科学院 | Tripeptides CGP with function of blood sugar reduction and application thereof |
| CN107011413B (en) * | 2017-05-31 | 2020-06-16 | 浙江省农业科学院 | Tripeptide CGP with blood sugar reducing function and application thereof |
| CN111187335A (en) * | 2019-09-19 | 2020-05-22 | 浙江省农业科学院 | Zein source dipeptide LK and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | Algal lectins as promising biomolecules for biomedical research | |
| CN111297900B (en) | Composition rich in adipose-derived stem cell exosomes and application thereof | |
| US8778422B2 (en) | Compositions for treating degenerative joint diseases | |
| CN103462864B (en) | Embryo water extract extracted from animal embryo internal organs, and extraction method and applications thereof | |
| CN105029429A (en) | Food additive enriched by gamma-aminobutyric acid and preparation method for food additive | |
| CN105238831A (en) | Moringa seed micro-molecular peptide extracted from moringa seeds, and extraction method thereof | |
| DE602004011047T2 (en) | CRYSTAL STRUCTURE FROM THE HUMAN CORONAVIRUS 229E MAIN PROTEINASE AND ITS USE IN THE DEVELOPMENT OF SARS INHIBITORS | |
| CN103992372A (en) | Dipeptide GT with function of decreasing blood glucose and application thereof | |
| CN102573885A (en) | Composition having lipolysis-promoting effect | |
| CN103992373A (en) | Dipeptide IF with blood sugar reducing function and application thereof | |
| CN103992375A (en) | Dipeptide QN with hypoglycemic function and use thereof | |
| CN105255985A (en) | Crocodile small molecule peptide extracted from bone of crocodile and extraction method of crocodile small molecule peptide | |
| JP2018115143A (en) | Fibroblast proliferation agent | |
| CN103992374A (en) | Dipeptide DI with double functions of reducing blood sugar and blood fat and application thereof | |
| CN1879652A (en) | Dried material and method for the manufacture thererof | |
| CN103468774B (en) | Method for separating alpha-glucosidase inhibitor from laver enzymolysis product | |
| CN107011413B (en) | Tripeptide CGP with blood sugar reducing function and application thereof | |
| CN110078793B (en) | Polypeptide with anti-aging and repairing functions and application thereof | |
| CN107011414B (en) | Tripeptide SPF with blood sugar reducing function and application thereof | |
| US20210393501A1 (en) | Preparation method and application of recombinant mutant collagenase | |
| CN105219831A (en) | A kind of yak small-molecular peptides of extracting from yak bone and extracting method thereof | |
| JP6049639B2 (en) | Chlorophyll c-containing degranulation inhibitor | |
| TWI670372B (en) | Medium composition for providing fermentation of α-glucosidase inhibitor by Bacillus licheniformis | |
| KR20190005653A (en) | Cosmetic composition for skin regeneration | |
| CN106389406B (en) | A kind of application of blood sugar reducing function compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140820 |
|
| RJ01 | Rejection of invention patent application after publication |